[ad_1]
Preliminary results from the Solidarity study, the largest therapeutic control trial on the planet, coordinated by the World Health Organization (WHO), indicate that the use of remdesivir, hydroxychloroquine, lopinavir / ritonavir, and interferon “appear to have little or no effect on 28-day mortality or the course of covid-19 among hospitalized patients.”
(You may be interested in: Covid-19: 151 more deaths and 6,823 new infections in Colombia)
This was revealed this Thursday by the WHO itself in a statement published on its official website, where it reveals that “the world’s largest randomized control trial of therapies for covid-19” after six months generated sufficient evidence on the effectiveness of the drugIt’s longstanding that were suggested as treatments for the new coronavirus.
The trials that included patients in more than 30 countries, including Colombia, analyzed the effects of these drugs against general indicators in those infected with Sars-CoV-2 such as general mortality, the start of mechanical ventilation and the length of hospital stay, among others.
(Read also: Rare case of deafness related to covid-19 documented)
While the trial data are under review for publication in a scientific journal, were released by WHO on a preliminary basis and it is concluded that “the remdesivir, hydroxychloroquine, lopinavir / ritonavir and interferon protocols have little or no effect on hospitalized patients with covid-19”, based on consistent results in a randomized evidence framework.
Specifically the results of remdesivir and interferon these conclusions “were consistent with the meta-analyzes of mortality in all the main trials”.
(Also read: Mathematicians ask for quality data to improve the study of covid-19)
Likewise, the effect of some of these drugs within the community as an element for the prevention of infection was analyzed. However, these data have not yet been consolidated, according to the WHO.
As revealed at the time by the National Institute for Food and Drug Surveillance (Invima), the treatment arms of the Solidaridad trial evaluated in Colombia were Remdesivir and Interferon, in five authorized institutions: Clínica Colombia, Clínica Infantil Santa María del Lago and Clínica Reina Sofía (Bogotá); Sebastián de Belalcazar Clinic (Cali) and Iberoamerica Clinic (Barranquilla).
HEALTH UNIT
